Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of our group over the years.

Early 2017: Acquisition of oncology assets from Merrimack Pharmaceuticals, a major step forward in bolstering Ipsen’s growing oncology presence and leveraging its oncology infrastructure in the United States.
Read more
Last update 17/11/2017